Iranian Biomedical Journal
مجله بیومدیکال ایران
IBJ
Basic Sciences
http://ibj.pasteur.ac.ir
1
admin
1028-852X
2008-823X
-
10.61186/ibj
-
8888
-
en
jalali
1396
6
1
gregorian
2017
9
1
21
5
online
1
fulltext
en
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer
Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer
Molecular Immunology & Vaccines
Molecular Immunology & Vaccines
مقاله کامل
Full Length/Original Article
<p><strong>Background: </strong>Gastric cancer arises, mainly, on an inflammatory background. <em>Helicobacter pylori </em>neutrophil activating (HP-NAP) protein functions as a potent pro-inflammatory mediator. Similarly, IL-4 plays a critical role in the inflammation pathway, the levels of which are altered by C to T transition at position -590 in its promoter region. Here, we have aimed to assess the risk of gastritis and gastric cancer in the co-presence of these two inflammation modulating mediators. <strong>Methods: </strong>Gastritis (n=58) and gastric cancer (n=31) patients were evaluated and compared with <em>H. pylori</em>-positive asymptomatic controls (n=46), for serum antibodies against recombinant HP-NAP and IL-4 C-590T single nucleotide polymorphism using immunoblotting and PCR-RFLP, respectively. Multivariable logistic regression, adjusting for age, gender and ethnicity, was used for data analysis. <strong>Results: </strong>In terms of susceptibility to gastritis, seropositivity to HP-NAP projected a risk impact of 4.62 fold (OR=4.62, 95% CI=1.50-14.22), which when present in IL-4 -590 T carriers augmented the risk up to 9.7 fold (OR=9.70, 95% CI=2.06-45.69). A similar pattern, but of a stronger magnitude, occurred for the risk of gastric cancer, which was estimated at 9.07 fold (OR=9.07, 95% CI=1.99-42.0) for HP-NAP-seropositive subjects and was drastically amplified (OR=33.64, 95% CI=2.06-548.68), when double-positive (HP-NAP seropositive/IL-4 -590 T carrier) subjects were examined against double negatives (HP-NAP seronegative/IL-4 -590 CC). <strong>Conclusion: </strong>Our preliminary data indicate that serum antibodies against HP-NAP represent a state of risk, which is further exacerbated in IL-4 -590 T carriers. These biomarkers, if validated in larger prospective studies, can be used to screen for gastric cancer susceptibility.</p>
Biomarkers, Genetic Polymorphism, Recombinant
321
329
http://ibj.pasteur.ac.ir/browse.php?a_code=A-10-1-641&slc_lang=en&sid=1
Yeganeh
Talebkhan
100319475328460055494
100319475328460055494
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Mohsen
Doozbakhshan
100319475328460055495
100319475328460055495
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Samaneh
Saberi
100319475328460055496
100319475328460055496
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Maryam
Esmaeili
100319475328460055497
100319475328460055497
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Najmeh
Karami
100319475328460055498
100319475328460055498
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Nazanin
Mohajerani
100319475328460055499
100319475328460055499
No
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
Afshin
Abdirad
100319475328460055500
100319475328460055500
No
Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
Mahmoud
Eshagh Hosseini
100319475328460055501
100319475328460055501
No
Department of Gastroenterology, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran
Azin
Nahvijou
100319475328460055502
100319475328460055502
No
Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
Mohammad Ali
Mohagheghi
100319475328460055503
100319475328460055503
No
Cancer Research Center, Tehran University of Medical Sciences, Tehran, Iran
Marjan
Mohammadi
100319475328460055504
100319475328460055504
Yes
HPGC Group, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran